Michel (Mike) Morency
Adler Pollock & Sheehan P.C.
Dr. Morency has over 25 years of legal practice with general corporate law firms, primarily in the life science industry. He holds a B.Sc. in Life Sciences, a Ph.D. in Medical Science – Neuroscience, and a J.D. in Common Law, providing him with a very strong educational background to represent life science companies. He has represented every segment of the life science industry, from early-stage companies to large multinational biopharmaceutical companies, as well as universities, and non-profit research organizations.
Dr. Morency advises clients on the creation and development of cost-effective, strategic intellectual property (IP) portfolios. He also provides counseling to life science companies in post-grant reviews, IP enforcement, and litigation issues, as well as preparing patent invalidity, freedom to operate and non-infringement opinions. His legal experience encompasses numerous technologies such as neurobiology, stem cell and transgenic technologies, immunology, and vaccine technologies, novel antibiotics, anti-viral therapeutics, cancer therapeutics, tissue and organ regeneration, blood cells and blood products, drug delivery, drug discovery, gene therapy, genomics, proteomics, nanotechnologies, antioxidants, and medical devices.
In addition to the creation and management of IP portfolios and related counseling, Dr. Morency has extensive experience in the commercialization of IP, including the negotiation and drafting of transactional agreements for the transfer of intellectual property rights, such as IP licenses, material transfer agreements, strategic collaborations, mergers and acquisitions, as well as conducting due diligence related to various financings and transactions. This extensive experience representing large biopharmaceutical companies, investors, and underwriters provides Dr. Morency with a unique insight on creating IP portfolios that meet and exceeds the industry expectations, which enhances the technology’s valuation.
- Patents
- Patent Appeals, Patent Litigation, Patent Prosecution
- Intellectual Property
- Business Law
- Business Contracts, Business Dissolution, Business Finance, Business Formation, Business Litigation, Franchising, Mergers & Acquisitions, Partnership & Shareholder Disputes
- Biotechnology & Pharmaceutical
- Private Equity & Venture Capital
- Free Consultation
- Massachusetts
- Massachusetts Board of Bar Overseers
- ID Number: 632204
-
- United States Patent and Trademark Office
- ID Number: 50,183
-
- Trusted IP and Transactional Life Science Strategist
- Adler Pollock & Sheehan P.C.
- - Current
- Partner | Boston Chair of IP Dept.
- Foley & Lardner LLP
- -
- Shareholder | Partner
- Greenberg Traurig, LLP
- -
- Member | Partner
- Mintz Levin
- -
- Associate
- Testa Hurwitz & Thibeault, LLP
- -
- University of Ottawa
- J.D. (1994) | Common Law
- -
- Honors: Cum Laude. Over 20 scholarships, awards, and academic prizes, including a Licensing Executive Society (LES) Fellowship; a Medical Research Council (MRC) Studentship (ranked first overall in the national competition); and a Natural Sciences & Engineering Research Council Postgraduate Scholarship.
-
- McMaster University
- Ph.D. (1992) | Medical Sciences - Neurosciences
- -
- Honors: Over 20 scholarships, awards, and academic prizes, including a Licensing Executive Society (LES) Fellowship; a Medical Research Council (MRC) Studentship (ranked first overall in the national competition); and a Natural Sciences & Engineering Research Council Postgraduate Scholarship.
-
- Queen's University
- B.S. (1984) | Life Sciences
- -
- Honors: With Honors. Over 20 scholarships, awards, and academic prizes, including a Licensing Executive Society (LES) Fellowship; a Medical Research Council (MRC) Studentship (ranked first overall in the national competition); and a Natural Sciences & Engineering Research Council Postgraduate Scholarship.
-
- Driving Revenue and Deal Flow Through an Intelligent IP Strategy: Strategies for• Smaller and Early-Stage Life Science Companies.
- The Licensing Journal, 41(1): 1‑9.
- How to Respond to a Cease and Desist Letter.
- NutraingredientUSA.com
- Patently Wise: What, How and Where to Patent.
- NutraingredientUSA.com
- Well-Written IP Strategy Puts Startups on Roadmap for Development.
- Mass High Tech
